See more : Farmers National Banc Corp. (FMNB) Income Statement Analysis – Financial Results
Complete financial analysis of 3D Medicines Inc. (1244.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 3D Medicines Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Orissa Bengal Carrier Limited (OBCL.NS) Income Statement Analysis – Financial Results
- Avalue Technology Incorporation (3479.TWO) Income Statement Analysis – Financial Results
- Gulf Alternative Energy Corp. (GAEC) Income Statement Analysis – Financial Results
- Tanger Inc. (SKT) Income Statement Analysis – Financial Results
- Seshasayee Paper and Boards Limited (SESHAPAPER.BO) Income Statement Analysis – Financial Results
3D Medicines Inc. (1244.HK)
About 3D Medicines Inc.
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 634.95M | 567.39M | 60.26M | 0.00 |
| Cost of Revenue | 110.94M | 42.22M | 4.28M | 0.00 |
| Gross Profit | 524.01M | 525.18M | 55.98M | 0.00 |
| Gross Profit Ratio | 82.53% | 92.56% | 92.90% | 0.00% |
| Research & Development | 425.50M | 350.86M | 373.70M | 263.97M |
| General & Administrative | 217.08M | 142.83M | 150.96M | 27.58M |
| Selling & Marketing | 378.81M | 357.66M | 42.83M | 0.00 |
| SG&A | 595.89M | 500.49M | 193.79M | 27.58M |
| Other Expenses | 0.00 | -717.17M | -957.11M | -319.23M |
| Operating Expenses | 585.86M | 846.54M | 559.07M | 303.93M |
| Cost & Expenses | 1.13B | 888.76M | 563.34M | 303.93M |
| Interest Income | 6.53M | 7.21M | 5.50M | 1.61M |
| Interest Expense | 7.77M | 3.11M | 1.53M | 8.06M |
| Depreciation & Amortization | 25.46M | 21.60M | 12.59M | 3.37M |
| EBITDA | -529.23M | -1.03B | -1.45B | -303.35M |
| EBITDA Ratio | -83.35% | -171.82% | -2,399.26% | 0.00% |
| Operating Income | -497.25M | -996.47M | -1.46B | -627.48M |
| Operating Income Ratio | -78.31% | -175.62% | -2,420.16% | 0.00% |
| Total Other Income/Expenses | -65.22M | -730.67M | -958.74M | -330.88M |
| Income Before Tax | -562.47M | -1.05B | -1.46B | -635.38M |
| Income Before Tax Ratio | -88.58% | -185.42% | -2,425.86% | 0.00% |
| Income Tax Expense | 55.00K | -27.68M | -27.73M | 0.00 |
| Net Income | -524.70M | -1.02B | -1.43B | -635.38M |
| Net Income Ratio | -82.64% | -180.54% | -2,379.84% | 0.00% |
| EPS | -2.30 | -22.52 | -36.72 | -13.93 |
| EPS Diluted | -2.30 | -22.52 | -36.72 | -13.93 |
| Weighted Avg Shares Out | 228.47M | 45.49M | 39.05M | 45.60M |
| Weighted Avg Shares Out (Dil) | 228.47M | 45.49M | 39.05M | 45.60M |
Source: https://incomestatements.info
Category: Stock Reports